Parikh Anand Kiran 4

What Happened

• Anand K. Parikh, President, CEO and a director of Faeth Therapeutics (FTH), acquired a mix of common shares on June 22, 2026. He purchased 2,806 shares in the open market at $19.76 each for $55,447, and exercised options to acquire 45,252 shares (cost $52,492) and 8,213 shares (cost $9,527). The exercises amounted to 53,465 shares paid for at $1.16 per share (total exercise cost ~$62,019). The filing also shows corresponding derivative dispositions at $0, which reflect conversion/cancellation of the derivative instruments upon exercise. Combined cash outlay reported ≈ $117,466.

Key Details

• Transaction date: 2026-06-22; Form filed: 2026-06-24 (timely filing).
• Open-market purchase: 2,806 shares at $19.76 each = $55,447.
• Option exercises (M): 45,252 shares at $1.16 = $52,492; 8,213 shares at $1.16 = $9,527.
• Derivative disposals at $0 correspond to the exercised derivative instruments (no cash proceeds).
• Shares owned after the transactions: not specified in the excerpt provided.
• Footnotes of note:
  • F1: Certain shares vest monthly (12,258 shares monthly from Mar 1, 2026 through Jan 1, 2027; remainder on Feb 1, 2027).
  • F2: This filing corrects a clerical error in a prior Form 4/A to show an expiration date of Dec 1, 2035.
  • F3: Option shares vest monthly in 48 equal installments beginning Aug 1, 2022.

Context

• The "M" codes indicate these were option exercises/conversions; the zero-dollar disposals are standard reporting when derivative instruments are converted into common stock (not a cash sale). The open-market purchase is an outright buy of common shares. Purchases and option exercises increase the insider's common-stock holdings and are generally considered more informative than routine sales, though this summary does not speculate on motives.